EXCLUSIVE: Sunshine Biopharma looks to the future in COVID and cancer treatments


Sunshine Biopharma Inc. SBFM could live the concept of being in the right place at the right time. This Canadian company is currently focused on three product lines – SBFM-PL4 COVID-19 treatment, cancer-fighting compound Adva-27a and Essential 9 nutritional supplements – and each is progressing with positive results.

In February, the company successfully closed an $8 million public offering and listed on the Nasdaq Capital Market. In addition, in February, the company entered into an agreement with the University of Arizona to pursue the development of novel inhibitors of PLpro used in its anti-cancer compound.

Earlier this month, Sunshine Biopharma announced that two of its newly designed mRNA molecules have been shown to be effective in terminating and destroying cancer cells grown in culture.

Cytotoxicity tests have been performed on different types of cancer cells, including those linked to breast, ovarian and prostate cancer. The company said it plans to file a patent application related to the test results.

Benzinga recently spoke with Camille SebaalyCFO of Sunshine Biopharma, on the current and future projects of the company.

Let’s start with your COVID treatment. What are your company’s immediate goals with this pursuit?

Camille Sebaaly: Our plan is to deliver a drug that works for almost everyone. And with all these coronaviruses surfacing, and there’s one – Omicron XE – that’s very difficult for a patient to manage. We think our PLpro is extremely good for this, and we think it’s the right medicine.

Congratulations are in order for the results of your anti-cancer compound. What is the primary focus of this aspect of your business?

Sebaaly: We are targeting multidrug resistance, and now we are focusing on pancreatic cancer because pancreatic cancer is the most dangerous.

Are you able to offer insight into your upcoming catalysts, including the human trials for COVID-19 and cancer programs?

Sebaaly: I can’t comment on it because it’s not in the public domain yet. It’s in progress, and it’s going to be announced.

Your company also offers the Essential 9 dietary supplement, which generated approximately $230,000 in fiscal 2021. What are your plans for this product line?

Sebaaly: We plan to do international marketing — a very aggressive marketing program. We are looking to sell a lot of this because it is a great product – it is called Essential 9 because it contains all nine amino acids that the body cannot make, and a deficiency in one or more of the nine essential amino acids can lead to loss of muscle mass, fatigue, weight gain, weakened immune system and reduced general well-being. It’s very good for everyone – I take it and look much younger than all my friends my age.

The company recently made headlines over a recent stock sale, which some people online blamed a article published by Benzinga. How do you think this sale happened?

Sebaaly: There was no reason to have a liquidation. I don’t know what triggered it. I do not know. The only thing I want to say is I’m sure they misunderstood Benzinga and short him [selling] people took advantage of it and they carried on. That’s all I can say.

Listening to you talk about Sunshine Biopharma resonates with your enthusiasm for your work. How does working with your company invigorate you personally?

Sebaaly: We have very good products, and we believe that we have something very interesting. And Dr. Steve Slilaty [the company’s CEO] is, to me, a genius. I’ve worked with him for over 30 years, and I believe anything he can do in half an hour takes other scientists at least four to six months to accomplish. He’s a brilliant guy.

I am very happy and I am very happy. I work day and night to deliver people, and we’re very compassionate about what we do.

If we were to resume this conversation a year from now, where would you see the company then?

Sebaaly: If things go as planned, we have a lot in the works. If one of them is fine and doing well, God knows where we will be next year — the limit is the sky here.

SBFM Price Action: The shares are down 15.3% at $2.93 at press time.

Photo courtesy of Sunshine Biopharma


Comments are closed.